BioVie Inc. (BIVI) stock
BIVINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as BIVIW
$0.80−0.11 (-12.07%)
Close on Nov 20, 2026Market cap $6.03MP/E –Yield –
BioVie net income
Net income is the profit left for shareholders after every expense, interest and tax.
BioVie's net income for the twelve months ending Jun 30, 2026 was -$22.07M. For fiscal 2026 it was -$22.07M. The highest annual figure on record is -$17.51K in fiscal 2013.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$22.07M | – |
| FY2025 | Jun 30, 2025 | -$17.54M | – |
| FY2024 | Jun 30, 2024 | -$32.12M | – |
| FY2023 | Jun 30, 2023 | -$50.26M | – |
| FY2022 | Jun 30, 2022 | -$26.08M | – |
| FY2021 | Jun 30, 2021 | -$130.25M | – |
| FY2020 | Jun 30, 2020 | -$16.68M | – |
| FY2018 | Jun 30, 2018 | -$2.43M | – |
| FY2017 | Jun 30, 2017 | -$1.33M | – |
| FY2016 | Jun 30, 2016 | -$431.92K | – |
| FY2015 | Jun 30, 2015 | -$233.01K | – |
| FY2014 | Jun 30, 2014 | -$321.90K | – |
| FY2013 | Jun 30, 2013 | -$17.51K | – |
Quarterly net income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$5.65M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$5.27M | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$6.07M | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$5.09M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$3.49M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$2.79M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$7.11M | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$4.15M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$4.94M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$8.07M | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$8.40M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$10.71M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$9.11M | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$15.04M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$15.69M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$10.42M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$8.09M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$7.04M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$5.41M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$5.54M | -175.5% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$131.53M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$2.99M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$3.06M | -145.9% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $7.33M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$19.15M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$366.40K | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $6.67M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$3.82M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$576.04K | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$692.56K | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$502.68K | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$662.84K | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$443.04K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$178.50K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$357.80K | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$351.34K | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$269.67K | – |
See a number that looks wrong?